Table 2.
Changes in lipid-modifying therapy
| Dose change | First event |
Second event
N (%) |
|||
|
Prior history of vascular disease
N (%) |
Prior history of diabetes
N (%) |
Prior history of vascular disease + diabetes
N (%) |
Other high risk
N (%) |
||
| n=7716 | n=2959 | n=2940 | n=5725 | n=3928 | |
| Statin | n=7380 | n=2807 | n=2773 | n=5470 | n=3725 |
| Switched therapy | 169 (2.29) | 51 (1.82) | 58 (2.09) | 103 (1.88) | 61 (1.64) |
| Augmented therapy | 268 (3.63) | 86 (3.06) | 108 (3.89) | 163 (2.98) | 157 (4.21) |
| Intensity decrease | 129 (1.75) | 34 (1.21) | 56 (2.02) | 82 (1.5) | 75 (2.01) |
| Intensity increase | 887 (12.02) | 399 (14.21) | 339 (12.23) | 874 (15.98) | 264 (7.09) |
| Ezetimibe | n=258 | n=101 | n=120 | n=161 | n=148 |
| Switched therapy | 30 (11.63) | 8 (7.92) | 16 (13.33) | 23 (14.29) | 16 (10.81) |
| Augmented therapy | 163 (63.18) | 59 (58.42) | 74 (61.67) | 88 (54.66) | 91 (61.49) |
| Fibrate | n=78 | n=51 | n=47 | n=94 | n=55 |
| Switched therapy | 9 (11.54) | 10 (19.61) | 5 (10.64) | 17 (18.09) | 6 (10.91) |
| Augmented therapy | 35 (44.87) | 20 (39.22) | 27 (57.45) | 33 (35.11) | 28 (50.91) |
Changes measured from first to last prescription in the 12-month follow-up period, ignoring gaps in therapy. Individuals receiving statins with ezetimibe were classified as statin users.